feed,title,long_url,short_url
Benzinga,BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market,https://benzinga.com/general/biotech/22/02/25802373/biomarin-clocks-flat-q4-sales-despite-erosion-of-us-kuvan-market,https://bit.ly/3HnIui4
Benzinga,"Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%",https://benzinga.com/news/22/02/25802074/insulet-posts-street-beating-q4-earnings-omnipod-revenues-up-20,https://bit.ly/3LWpLNM
Benzinga,EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application,https://benzinga.com/general/biotech/22/02/25801500/emas-advisory-committee-does-not-back-orphazymes-arimoclomol-application,https://bit.ly/3sfRL7f
